Table 2.

Clinical characteristics of subjects born after 1997 infected with Cluster A or Cluster B MRSA.

Characteristic	Cluster A N = 20	Cluster B N = 12	P
Age, years† Median [IQR]	13.6 [10.4 – 16.4]	11.1 [9.0 – 17.1]	0.50*
MRSA acquisition date, Median [IQR]	09/2009 [7/2007 – 02/2015]	08/2013 [12/2011 – 03/2015]	0.14*
Female Sex	10 (50%)	4 (33%)	0.48‡
Genotype			0.62‡
ΔF508/ΔF508	11 (55%)	6 (50%)
ΔF508/other	7 (35%)	6 (50%)
Other/other	2 (10%)	0
Sputum production, N (%)	15 (75%)	10 (83%)	0.68‡
P. aeruginosa N (%)	11 (55%)	6 (50%)	1.0‡
Spirometry performed, N (%)	19 (95%)	12 (100%)	1.0‡
Medications in 2017
Trimethoprim/Sulfamethoxazole	12 (60%)	10 (83%)	0.25‡
Linezolid	14 (70%)	5 (42%)	0.15‡
Doxycycline	10 (50%)	1 (8.3%)	0.02‡
Vancomycin IV	9 (45%)	6 (50%)	1.0‡
Tobramycin inhaled	14 (70%)	7 (58%)	0.70‡
Ciprofloxacin	9 (45%)	4 (33%)	0.72‡
Azithromycin	19 (95%)	11 (92%)	1.0‡
Ivacaftor	2 (10%)	2 (17%)	0.62‡
Lumacaftor/Ivacaftor	11 (55%)	5 (42%)	0.72‡

^†Age determined on July 1, 2017. No subjects had lung transplant or CFTR related metabolic syndrome. P values determined by

^*Wilcoxon rank sum test or

^‡Fisher’s exact test.